First patient enrolled in the U.S. Arise Study for the treatment of knee osteoarthritis, announced by LIPOGEMS

author
1 minute, 48 seconds Read

Lipogems announced that the first patient would be enrolled into the ARISE U.S. FDA IDE Study by January 13, 2023. The study compares MicroFat injections with steroid ones for treating Knee Osteoarthritis.

It’s a great time! “We screened this patient on December 30, 2022, and I’m proud to have enrolled the first patient,” stated Dr. YogeshMittal. He is Board Certified in Total Joint Surgery and has received Fellowship Training at The Orthopaedic Clinic in Tulsa, Oklahoma. This is a NextStage Clinical Research Site. Many patients with Knee OA don’t have the time to undergo total knee arthroplasty. After they have tried conservative treatments like corticosteroids or HA injections, I can only offer them a limited number of options. Lipogems can be used as a single treatment to delay TKA in these patients.

Patients with knee OA who have not been able to find relief from their pain or reduced quality of life may also suffer from other chronic diseases manifested by inactivity and depression.

Dr. YogeshMittal is the first Orthopaedic Surgeon to enroll a patient in the Lipogems ARISE Study. The study compares MicroFat with corticosteroid in the treatment of knee osteoarthritis.

The Lipogems FDA IDE Study ARISE aims to assess the safety and efficacy of Lipogems in order to determine a specific indication to treat Knee OA. Up to 20 U.S. study sites will be involved. The study will compare the effects on pain and function of a single autologous intra-articular injection of Lipogems proprietary MicroFat versus a steroid in patients with moderate Knee OA.

The ARISE study is going to prove that we are able to help patients who have Knee OA. It is crucial because these patients live longer, are more active and lead a very busy life. The product is available for orthopaedic use. A Knee OA-specific indication would allow us to better serve the patients who are underserved and help them manage this debilitating disease.

Reference:

  • London NJ, Miller LE, and Block JE. The economic and clinical implications of treatment gaps for knee osteoarthritis. Med Hypotheses. 2011 Jun;76(6):887-92. doi: 10.1016/j.mehy.2011.02.044. Epub 2011 Mar 25. PMID: 21440373.

Similar Posts